| Control group (n = 35) | Bicarbonate group (n = 35) | P value |
---|---|---|---|
Demographics | |||
 Age (years) | 55.1 ± 15.7 | 53.9 ± 14.1 | 0.738 |
 Sex (male:female) | 27:8 | 21:14 | 0.122 |
 Body mass index (kg/m2) | 21.6 ± 3.6 | 22.0 ± 3.3 | 0.613 |
Cormobidities | |||
 Hypertension | 10 | 10 | >0.999 |
 Diabetes mellitus | 6 | 4 | 0.495 |
 Congestive heart failure | 1 | 0 | 0.314 |
 Chronic kidney disease (SCr >1.4 mg/dl) | 7 | 8 | 0.771 |
 MI within 1 month | 0 | 0 |  |
 Cerebrovascular disease | 5 | 3 | 0.452 |
 COPD | 0 | 0 |  |
 Repeat surgery | 4 | 6 | 0.495 |
Preoperative condition | |||
 Left ventricular ejection fraction (%) | 63.9 ± 8.5 | 65.9 ± 7.4 | 0.312 |
 EuroSCORE | 4 (2, 9) | 5 (3, 8) | 0.449 |
 Cleveland Clinic scorea | 2 (1, 3) | 2 (1, 2) | 0.360 |
 Vancomycin or aminoglycoside | 27 | 29 | 0.550 |
 Contrast use 48 h prior to surgery | 19 | 14 | 0.231 |
 Hemoglobin below 10 g/dl | 14 | 8 | 0.122 |
 Platelets below 100,000/μl /150,000/μl | 3/ 11 | 1/ 3 | 0.303/0.017 |
 Embolic events | 8 | 13 | 0.192 |
 Prosthetic valve infection | 4 | 6 | 0.495 |
 Active infectionb/emergencyc | 27/ 4 | 29/ 4 | 0.555/>0.999 |
Medications | |||
 ACEi/ARB | 8 | 8 | >0.999 |
 β-blockers | 7 | 8 | 0.771 |
 Calcium channel blockers | 3 | 4 | 0.690 |
 Diuretics | 12 | 14 | 0.621 |
 Antiplatelet drugs | 5 | 0 | 0.020 |
Operation | Â | Â | Â |
 Aortic valve replacement | 11 | 7 | 0.274 |
 Mitral valve replacement | 17 | 19 | 0.632 |
 Double valve operation | 4 | 2 | 0.393 |
 Tricuspid annuloplasty | 2 | 3 | 0.643 |
 Valve + aorta | 1 | 4 | 0.164 |